COVID-19 Update: Vaccine notifications will go through MyScripps and email — please do not call your doctor. Learn more.
Combined Immunotherapy and Chemotherapy for Muscle-invasive Bladder Cancer
In response to the COVID pandemic, Scripps Health has either temporarily suspended or limited enrollment with appropriate precautions for all clinical trials. For questions, please call Scripps Office for the Protection of Research Subjects at 858-678-6402.
Munveer S Bhangoo, MD
This study will test the effectiveness of Pembrolizumab (KEYTRUDA) given before and after surgery for the treatment of muscle-invasive bladder cancer. Pembrolizumab is used as an immune-enhancing medication, that may block immune pathways for tumor growth.
Be 18 years of age or older
Have a confirmed diagnosis of Muscle – invasive Bladder Cancer (MIBC), Clinical Stage T2-T4aN0M0
Must be eligible to receive cisplatin chemotherapy.
Be eligible for surgical treatment and agree to planned surgical treatment
Have received any prior systemic anti-cancer treatment for MIBC
Be pregnant or breastfeeding or expecting to conceive or father children within the defined study duration
Have a known history of HIV, Hepatitis B, or active Hepatitis C
All patients will receive chemotherapy (cisplatin + gemcitabine) and surgery and will be randomly selected to receive either pembrolizumab or placebo.
All treatments and physician visits during this study will take place at Scripps Clinic Torrey Pines. Study treatment will occur for approximately 1 year and patients will be followed for up to 5 years after treatment has ended.
For more information, search for NCT03924856 at www.clinicaltrials.gov